Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Change in Receivables (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Change in Receivables for 3 consecutive years, with -$1.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables changed N/A to -$1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.1 million, a N/A change, with the full-year FY2025 number at $1.5 million, changed N/A from a year prior.
  • Change in Receivables was -$1.4 million for Q4 2025 at Outlook Therapeutics, down from -$260491.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of -$260491.0 in Q3 2025 to a low of -$1.4 million in Q4 2025.